AbbVie Inc.
NASDAQ: ABBVKey stats
Price chart
About AbbVie Inc.
Biotechnology
Company profile
- IPO date
- Jan 2, 2013
- Website
- www.abbvie.com
Healthcare peers
How ABBV compares to other large companies in the same sector.
| Company | Price | Today | Market cap | P/E |
|---|---|---|---|---|
 LLY Eli Lilly and Company | $1004.92 | -0.18% | $946.37B | 37.44 |
 JNJ Johnson & Johnson | $226.71 | -1.77% | $549.56B | 26.34 |
 UNH UnitedHealth Group | $393.85 | -1.31% | $358.78B | 30.14 |
 MRK Merck & Co. | $111.38 | -1.79% | $275.09B | 30.79 |
 PFE Pfizer Inc. | $25.33 | -1.63% | $144.17B | 19.57 |
Wall Street analyst ratings
DollarScout analysis
Editorial, not advice. See our methodology.
Bull case
AbbVie has a robust product portfolio that includes well-known drugs like Humira, Skyrizi, and Rinvoq, which have shown strong sales performance. Humira, while facing biosimilar competition, remains a key revenue driver. The company's focus on expanding its immunology and oncology pipeline is a testament to its competitive moat and innovation strength. AbbVie is also investing in new therapies with promising clinical studies, potentially diversifying its revenue streams. The strong dividend yield of 3.1694% also adds a layer of appeal to income-focused investors seeking reliable payouts.
Bear case
AbbVie's P/E ratio of 87.03 is significantly higher than many peers, suggesting the stock could be overvalued if growth doesn't meet expectations. While Humira has historically been a cash cow, its revenue is under threat from generic competition, especially in international markets. The company's reliance on a few flagship drugs exposes it to substantial risk if these drugs face regulatory pushback, patent cliffs, or competition. The pharmaceutical industry is intensely competitive, with fierce players like Pfizer and Johnson & Johnson aiming for market share in similar segments. Additionally, changing healthcare policies and pricing pressures pose risks to profitability.
Who should buy ABBV
AbbVie might suit long-term dividend investors who can tolerate high volatility and prioritize regular income. Suitable for those with a 5+ year horizon looking to benefit from a strong dividend yield and potential capital appreciation from pharmaceutical innovations. It may also appeal to those who believe in the company's strong R&D pipeline and the ability to bring new successful drugs to market.
Key risks
- Heavy reliance on a few key products like Humira for revenue. - Potential overvaluation reflected in high P/E ratio. - Increasing biosimilar competition in the immunology sector. - Regulatory challenges and healthcare policy changes that could impact pricing and profitability.
Where to buy ABBV
Open an account with a broker we've reviewed and start trading AbbVie Inc. today.
Want to practice first? Try the free Stock Trading Simulator with $100,000 virtual cash.
Recent ABBV news
Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In this context of robust market performance, identifying stocks that are trading below their fair value can be a strategic move for investors seeking opportunities for potential growth and value.
AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set them apart.
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.
ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.
Realty Income (NYSE:O) is dominating dividend feeds on Reddit and X again, with monthly-payer loyalists pointing to its 113th consecutive quarterly dividend increase as proof you can collect a check and tune out the rest of the market. The underlying numbers tell a different story. The Math On O Has Quietly Broken O trades at ... Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now
Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.
ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.
Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and lowers the price target from $236 to $235.
Disclaimer: The information on this page is provided for informational and educational purposes only and should not be considered financial, investment, or trading advice. DollarScout does not recommend buying or selling any specific security. Stock data may be delayed. Past performance is not indicative of future results. Always do your own research and consult a licensed financial advisor before making investment decisions.